{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:04:44Z","timestamp":1788174284211,"version":"build-2803163510"},"reference-count":41,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRR"],"published-print":{"date-parts":[[2020,3,5]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Up to 44% of patients treated with infliximab and 7% of patients treated\nwith etanercept reported to have anti-drug antibodies within the first 6 months of treatment. Recently,\nanti-TNF-\u03b1 therapies have been reported to be employed in the induction of the druginduced\nlupus erythematous.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p> The aim of the present study was to investigate the relationship between anti-TNF\u03b1 antibodies\nand various manifestations of lupus erythematous.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title> Methods:<\/jats:title>\n<jats:p>We enrolled a total of 56 cases divided into 28 known cases of rheumatoid arthritis and\n28 cases of ankylosing spondylitis patients and 56 controls. The case group was divided into 4\ngroups according to the underlying disease (RA or AS) and treatment regimen (infliximab or etanercept).\nANA and anti-dsDNA levels and lupus criteria were assessed at the beginning of the study\nand 4 months after the initiation of anti-TNF\u03b1.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>36% and 21% of RA patients treated with infliximab, were ANA and anti-dsDNA positive\nafter 4 months (P=0.003, P=0.025). 28% and 7% of RA patients treated with etanercept, were ANA\nand anti-dsDNA positive after 4 months (P=0.009, P=0.15). 21% and 7% of AS patients treated\nwith infliximab, were ANA and anti-dsDNA positive, respectively (P=0.025, P=0.15). 14% and 7%\nof AS patients treated with etanercept, were ANA and anti-dsDNA positive, respectively (P=0.63,\nP=0.15). Three patients who were positive for auto-antibodies developed three criteria for SLE.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title> Conclusions:<\/jats:title>\n<jats:p>Infliximab potentially may increase both ANA and anti-dsDNA levels in rheumatoid\narthritis, but only ANA in ankylosing spondylitis patients. In general, clinicians should consider\ndifferent clinical symptoms of ATIL, which may be present as a lupus-like syndrome similar to\nidiopathic SLE or classical DIL.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573397115666190506152729","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T07:36:13Z","timestamp":1557214573000},"page":"61-66","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Antinuclear Antibodies and Lupus-like Manifestations in Rheumatoid Arthritis and Ankylosing Spondylitis Patients at 4 Months' Follow-up After Treatment with Infliximab and Etanercept"],"prefix":"10.2174","volume":"16","author":[{"given":"Mir Amir","family":"Aghdashi","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Khadir","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Imam Khomeini Hospital, Urmia University of Medical Sciences, Urmia, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Dinparasti-Saleh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Imam Khomeini Hospital, Urmia University of Medical Sciences, Urmia, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jaut.2009.09.008","volume":"33","author":"Cooper G.S.","year":"2009","unstructured":"Cooper G.S.; Bynum M.L.; Somers E.C.; Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun 2009,33(3-4),197-207","journal-title":"J Autoimmun"},{"key":"ref=2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011531","volume":"97","author":"Zhu B.","year":"2018","unstructured":"Zhu B.; Zhu Q.; Li N.; Wu T.; Liu S.; Liu S.; Association of serum\/plasma high mobility group box 1 with autoimmune diseases: A systematic review and meta-analysis. Medicine (Baltimore) 2018,97(29)","journal-title":"Medicine (Baltimore)"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"McInnes I.B.","year":"2011","unstructured":"McInnes I.B.; Schett G.; The pathogenesis of rheumatoid arthritis. N Engl J Med 2011,365(23),2205-2219","journal-title":"N Engl J Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1093\/rheumatology\/41.1.88","volume":"41","author":"Carmona L.","year":"2002","unstructured":"Carmona L.; Villaverde V.; Hern\u00e1ndez-Garc\u00eda C.; Ballina J.; Gabriel R.; Laffon A.; EPISER Study Group.The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology (Oxford) 2002,41(1),88-95","journal-title":"Rheumatology (Oxford)"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"S265","DOI":"10.1186\/ar578","volume":"4","author":"Silman A.J.","year":"2002","unstructured":"Silman A.J.; Pearson J.E.; Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 2002,4(Suppl. 3),S265-S272","journal-title":"Arthritis Res"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.rdc.2017.04.006","volume":"43","author":"Hanson A.","year":"2017","unstructured":"Hanson A.; Brown M.A.; Genetics and the causes of ankylosing spondylitis. Rheum Dis Clin North Am 2017,43(3),401-414","journal-title":"Rheum Dis Clin North Am"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40674-016-0055-6","volume":"2","author":"Hinze A.M.","year":"2016","unstructured":"Hinze A.M.; Louie G.H.; Osteoporosis management in ankylosing spondylitis. Curr Treatm Opt Rheumatol 2016,2(4),271-282","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0049-0172(05)80011-3","volume":"22","author":"Gran J.T.","year":"1993","unstructured":"Gran J.T.; Husby G.; The epidemiology of ankylosing spondylitis. Semin Arthritis Rheum 1993,22(5),319-334","journal-title":"Semin Arthritis Rheum"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1146\/annurev.iy.07.040189.003205","volume":"7","author":"Beutler B.","year":"1989","unstructured":"Beutler B.; Cerami A.; The biology of cachectin\/TNF--a primary mediator of the host response. Annu Rev Immunol 1989,7,625-655","journal-title":"Annu Rev Immunol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1056\/NEJM200103223441207","volume":"344","author":"Choy E.H.","year":"2001","unstructured":"Choy E.H.; Panayi G.S.; Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001,344(12),907-916","journal-title":"N Engl J Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2249.1993.tb05992.x","volume":"94","author":"Shingu M.","year":"1993","unstructured":"Shingu M.; Nagai Y.; Isayama T.; Naono T.; Nobunaga M.; Nagai Y.; The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin Exp Immunol 1993,94(1),145-149","journal-title":"Clin Exp Immunol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(09)60008-8","volume":"373","author":"Klareskog L.","year":"2009","unstructured":"Klareskog L.; Catrina A.I.; Paget S.; Rheumatoid arthritis. Lancet 2009,373(9664),659-672","journal-title":"Lancet"},{"key":"ref=13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030768","volume":"19","author":"Lim H.","year":"2018","unstructured":"Lim H.; Lee S.H.; Lee H.T.; Structural biology of the TNF\u03b1 antagonists used in the treatment of rheumatoid arthritis. Int J Mol Sci 2018,19(3)","journal-title":"Int J Mol Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"Singh J.A.","year":"2016","unstructured":"Singh J.A.; Saag K.G.; Bridges S.L.; 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016,68(1),1-26","journal-title":"Arthritis Rheumatol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"Sieper J.","year":"2017","unstructured":"Sieper J.; Poddubnyy D.; Axial spondyloarthritis. Lancet 2017,390(10089),73-84","journal-title":"Lancet"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/0161-5890(93)90106-L","volume":"30","author":"Knight D.M.","year":"1993","unstructured":"Knight D.M.; Trinh H.; Le J.; Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993,30(16),1443-1453","journal-title":"Mol Immunol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1124\/dmd.114.062901","volume":"43","author":"Chen X.","year":"2015","unstructured":"Chen X.; DuBois D.C.; Almon R.R.; Jusko W.J.; Biodistribution of etanercept to tissues and sites of inflammation in arthritic rats. Drug Metab Dispos 2015,43(6),898-907","journal-title":"Drug Metab Dispos"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jemermed.2005.01.033","volume":"30","author":"Gamarra R.M.","year":"2006","unstructured":"Gamarra R.M.; McGraw S.D.; Drelichman V.S.; Maas L.C.; Serum sickness-like reactions in patients receiving intravenous infliximab. J Emerg Med 2006,30(1),41-44","journal-title":"J Emerg Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1136\/ard.2008.092833","volume":"68","author":"Radstake T.R.","year":"2009","unstructured":"Radstake T.R.; Svenson M.; Eijsbouts A.M.; Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009,68(11),1739-1745","journal-title":"Ann Rheum Dis"},{"key":"ref=20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175207","volume":"12","author":"Moots R.J.","year":"2017","unstructured":"Moots R.J.; Xavier R.M.; Mok C.C.; The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PLoS One 2017,12(4)","journal-title":"PLoS One"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1002\/art.22214","volume":"54","author":"Bendtzen K.","year":"2006","unstructured":"Bendtzen K.; Geborek P.; Svenson M.; Larsson L.; Kapetanovic M.C.; Saxne T.; Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006,54(12),3782-3789","journal-title":"Arthritis Rheum"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1590\/abd1806-4841.20153893","volume":"90","author":"Quaresma M.V.","year":"2015","unstructured":"Quaresma M.V.; Bernardes Filho F.; Oliveira F.B.; Pockstaller M.P.; Dias M.F.; Azulay D.R.; Anti-TNF-\u03b1 and hydralazine drug-induced lupus. An Bras Dermatol 2015,90(3)(Suppl. 1),125-129","journal-title":"An Bras Dermatol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10067-015-3140-6","volume":"35","author":"Vaz J.L.","year":"2016","unstructured":"Vaz J.L.; Fernandes V.; Nogueira F.; Arn\u00f3bio A.; Levy R.A.; Infliximab-induced autoantibodies: a multicenter study. Clin Rheumatol 2016,35(2),325-332","journal-title":"Clin Rheumatol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"Aletaha D.","year":"2010","unstructured":"Aletaha D.; Neogi T.; Silman A.J.; Rheumatoid arthritis classification criteria: an American college of rheumatology\/European league against rheumatism collaborative initiative. Arthritis Rheum 2010,62(9),2569-2581","journal-title":"Arthritis Rheum"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"Rudwaleit M.","year":"2011","unstructured":"Rudwaleit M.; van der Heijde D.; Landew\u00e9 R.; The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011,70(1),25-31","journal-title":"Ann Rheum Dis"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"Petri M.","year":"2012","unstructured":"Petri M.; Orbai A.M.; Alarc\u00f3n G.S.; Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012,64(8),2677-2686","journal-title":"Arthritis Rheum"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"van Gestel A.M.","year":"1996","unstructured":"van Gestel A.M.; Prevoo M.L.; van \u2019t Hof M.A.; van Rijswijk M.H.; van de Putte L.B.; van Riel P.L.; Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism Criteria. Arthritis Rheum 1996,39(1),34-40","journal-title":"Arthritis Rheum"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/ard.2008.094870","volume":"68","author":"Lukas C.","year":"2009","unstructured":"Lukas C.; Landew\u00e9 R.; Sieper J.; Assessment of SpondyloArthritis international Society. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009,68(1),18-24","journal-title":"Ann Rheum Dis"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/intimm\/dxu102","volume":"27","author":"Monaco C.","year":"2015","unstructured":"Monaco C.; Nanchahal J.; Taylor P.; Feldmann M.; Anti-TNF therapy: past, present and future. Int Immunol 2015,27(1),55-62","journal-title":"Int Immunol"},{"key":"ref=30","author":"Corbett M","unstructured":"Corbett M; Soares M; Jhuti G; Rice S; Spackman E; Sideris E;  Tumour necrosis factor-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluationHealth technology assessment (Winchester, England) 2016 Feb; 20(9): 1-334 v-vi","journal-title":"Tumour necrosis factor-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluationHealth technology assessment (Winchester, England) 2016 Feb; 20(9): 1-334 v-vi"},{"key":"ref=31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18091973","volume":"18","author":"Lopetuso L.R.","year":"2017","unstructured":"Lopetuso L.R.; Gerardi V.; Papa V.; Can We Predict the Efficacy of Anti-TNF-\u03b1 Agents? Int J Mol Sci 2017,18(9)","journal-title":"Int J Mol Sci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/00002281-200305000-00014","volume":"15","author":"Ziolkowska M.","year":"2003","unstructured":"Ziolkowska M.; Maslinski W.; Laboratory changes on anti-tumor necrosis factor treatment in rheumatoid arthritis. Curr Opin Rheumatol 2003,15(3),267-273","journal-title":"Curr Opin Rheumatol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ibd.21362","volume":"17","author":"Beigel F.","year":"2011","unstructured":"Beigel F.; Schnitzler F.; Paul Laubender R.; Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-\u03b1 antibody-treated patients with inflammatory bowel disease. Inflamm Bowel Dis 2011,17(1),91-98","journal-title":"Inflamm Bowel Dis"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383:AID-ANR2>3.0.CO;2-D","volume":"43","author":"Charles P.J.","year":"2000","unstructured":"Charles P.J.; Smeenk R.J.; De Jong J.; Feldmann M.; Maini R.N.; Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000,43(11),2383-2390","journal-title":"Arthritis Rheum"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"R545","DOI":"10.1186\/ar1715","volume":"7","author":"De Bandt M.","year":"2005","unstructured":"De Bandt M.; Sibilia J.; Le Lo\u00ebt X.; Club Rhumatismes et Inflammation. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005,7(3),R545-R551","journal-title":"Arthritis Res Ther"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.autrev.2009.10.003","volume":"9","author":"Ramos-Casals M.","year":"2010","unstructured":"Ramos-Casals M.; Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA. BIOGEAS study group. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 2010,9(3),188-193","journal-title":"Autoimmun Rev"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1196\/annals.1422.019","volume":"1108","author":"Borchers A.T.","year":"2007","unstructured":"Borchers A.T.; Keen C.L.; Gershwin M.E.; Drug-induced lupus. Ann N Y Acad Sci 2007,1108,166-182","journal-title":"Ann N Y Acad Sci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","volume":"86","author":"Ramos-Casals M.","year":"2007","unstructured":"Ramos-Casals M.; Brito-Zer\u00f3n P.; Mu\u00f1oz S.; Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007,86(4),242-251","journal-title":"Medicine (Baltimore)"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"Tan E.M.","year":"1982","unstructured":"Tan E.M.; Cohen A.S.; Fries J.F.; The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982,25(11),1271-1277","journal-title":"Arthritis Rheum"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00296-012-2617-8","volume":"34","author":"Akg\u00fcl \u00d6.","year":"2014","unstructured":"Akg\u00fcl \u00d6.; K\u0131l\u0131\u00e7 G.; K\u0131l\u0131\u00e7 E.; C\u00fcce \u0130.; \u00d6zg\u00f6\u00e7men S.; A patient with ankylosing spondylitis who developed infliximab-induced lupus and treated with etanercept. Rheumatol Int 2014,34(3),443-444","journal-title":"Rheumatol Int"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1365-4632.2011.04871.x","volume":"50","author":"Williams V.L.","year":"2011","unstructured":"Williams V.L.; Cohen P.R.; TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol 2011,50(5),619-625","journal-title":"Int J Dermatol"}],"container-title":["Current Rheumatology Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/172008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T08:28:30Z","timestamp":1585384110000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/172008\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573397115666190506152729","relation":{},"ISSN":["1573-3971"],"issn-type":[{"value":"1573-3971","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}